Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

1.

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

Moran T, Sequist LV.

J Clin Oncol. 2012 Sep 20;30(27):3330-6. doi: 10.1200/JCO.2012.43.1858. Epub 2012 Jul 2. No abstract available.

PMID:
22753908
[PubMed - indexed for MEDLINE]
Free Article
2.

Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma.

Hong T, Zhang R, Cai D, Wu X, Hua D.

J Cancer Res Clin Oncol. 2012 Feb;138(2):285-91. doi: 10.1007/s00432-011-1084-z. Epub 2011 Nov 25.

PMID:
22116317
[PubMed - indexed for MEDLINE]
3.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
[PubMed - indexed for MEDLINE]
4.

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.

Heuckmann JM, Rauh D, Thomas RK.

J Clin Oncol. 2012 Sep 20;30(27):3417-20. doi: 10.1200/JCO.2012.43.1825. Epub 2012 Aug 20. No abstract available.

PMID:
22915655
[PubMed - indexed for MEDLINE]
Free Article
5.

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.

Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15.

PMID:
20008840
[PubMed - indexed for MEDLINE]
Free Article
6.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Moldvay J, Peták I.

Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15. Hungarian.

PMID:
22403761
[PubMed - indexed for MEDLINE]
Free Article
7.

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W.

J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607.

PMID:
18303429
[PubMed - indexed for MEDLINE]
8.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

Chiari R, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crinò L.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13. No abstract available.

PMID:
24419120
[PubMed - indexed for MEDLINE]
9.

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J.

J Clin Oncol. 2012 Sep 1;30(25):3077-83. doi: 10.1200/JCO.2011.39.3744. Epub 2012 Jul 23.

PMID:
22826274
[PubMed - indexed for MEDLINE]
Free Article
10.

Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Filosto S, Becker CR, Goldkorn T.

Mol Cancer Ther. 2012 Apr;11(4):795-804. doi: 10.1158/1535-7163.MCT-11-0698. Epub 2012 Feb 1.

PMID:
22302097
[PubMed - indexed for MEDLINE]
Free Article
11.

[Overcoming resistance to EGFR-TKI in lung cancer].

Takeda K.

Gan To Kagaku Ryoho. 2009 Apr;36(4):552-6. Japanese.

PMID:
19381026
[PubMed - indexed for MEDLINE]
12.

Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.

Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.

J Thorac Oncol. 2012 Jul;7(7):1078-85. doi: 10.1097/JTO.0b013e3182519a2c.

PMID:
22592212
[PubMed - indexed for MEDLINE]
13.

Molecular pathology of lung cancer: key to personalized medicine.

Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S.

Mod Pathol. 2012 Mar;25(3):347-69. doi: 10.1038/modpathol.2011.215. Epub 2012 Jan 27. Review.

PMID:
22282308
[PubMed - indexed for MEDLINE]
Free Article
14.

Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?

Hata A, Kaji R, Fujita S, Katakami N.

J Thorac Oncol. 2011 Feb;6(2):404. doi: 10.1097/JTO.0b013e318204a1dc. No abstract available.

PMID:
21252723
[PubMed - indexed for MEDLINE]
15.

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.

Cancer Res. 2007 Nov 1;67(21):10417-27.

PMID:
17974985
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors.

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH.

Chemotherapy. 2011;57(2):108-14. doi: 10.1159/000321490. Epub 2011 Mar 18.

PMID:
21411993
[PubMed - indexed for MEDLINE]
18.

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.

Ansén S, Bangard C, Querings S, Gabler F, Scheffler M, Seidel D, Saal B, Zander T, Nogová L, Töpelt K, Markert E, Stoelben E, Ernestus K, Thomas RK, Wolf J.

J Thorac Oncol. 2010 Mar;5(3):407-9. doi: 10.1097/JTO.0b013e3181cf32aa. No abstract available. Erratum in: J Thorac Oncol. 2010 Jun;5(6):926.

PMID:
20186030
[PubMed - indexed for MEDLINE]
19.

Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.

Ohtsuka K, Ohnishi H, Morii T, Fujiwara M, Kishino T, Ogura W, Chiba M, Matsushima S, Goya T, Watanabe T.

J Thorac Oncol. 2010 Nov;5(11):1726-33. doi: 10.1097/JTO.0b013e3181f0b6af.

PMID:
20975373
[PubMed - indexed for MEDLINE]
20.

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Giaccone G, Rodriguez JA.

Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. Review.

PMID:
16270096
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk